The present disclosure generally relates to nanoparticles comprising an endo-lysosomal escape agent, a nucleic acid, and a polymer. Other aspects include methods of making and using such nanoparticles.

Polymer conjugates are provided that are capable of mimicking functions of natural proteoglycans found in the extracellular matrix of connective tissues. The polymer conjugates of the invention have utility in treating a subject suffering soft tissue degenerative conditions. Also provided are simple and scalable chemical processes for the preparation of the polymer conjugates of the invention.

Compositions that comprise salts, compounds and complexes of .sup.64Zn-enriched zinc, such as .sup.64Zn-enriched zinc aspartate, and further optionally include .sup.85Rb-enriched rubidium salt compounds of general formula 1, below, wherein each of R.sub.1 through R.sub.14 is independently selected from H, OH, F, Cl, Br, I, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxy, and NO.sub.2, such as the compound of Formula 1 in which R.sub.3 is CH.sub.3 and all other R groups are H for use to treat a neurodegenerative disease (NDD), such as Parkinson's disease (PD). Methods that entail administering such compositions to treat an NDD, such as PD, optionally in combination with any other treatment for an NDD such as for PD. ##STR00001##

The present invention is related to a method for treating cancer by using siRNA nanocomplexes. The present nanocomplex consists of a nucleic acid molecule, a monocationic drug and a biocompatible polymer surfactant, and not only has a hydrodynamic size of 10 nm or less, but uniformly distributes as a colloidal form in an aqueous environment. In addition, the nanoscale colloidal formulation of the present invention could protect the nucleic acid molecule from a nuclease (for example, serum nucleases) rich in a physiological environment through the formulation of a stable monocomplex, and provide improvement of cell penetration and in vivo delivery via a micellar structure as well as further protection of the nucleic acid molecule by a micellar passivation. Therefore, the present nanocomplex and a composition and system using the same can deliver an active ingredient (for example, a nucleic acid molecule and monocationic drug) into a cell/tissue of interest in a stable manner, and may be effectively applied for treating or detecting diverse disorders (practically, cancers).

The present disclosure is directed to a method of making a composition by combining a vehicle, e.g., a single phase vehicle, and an insoluble component comprising a beneficial agent, and sterilizing the composition using ionizing radiation prior to use, wherein the beneficial agent is stable following exposure to a sterilizing dose of ionizing radiation. Related compositions and methods are provided.

Provided herein are, inter alia, compositions and methods useful for the in vivo delivery of bioactive agents (e.g., therapeutic or diagnostic agents). The compositions provided herein include cationic lipids, helper lipids and a biostability enhancing agent, which together form a lipid aggregate with the bioactive agent and allow for the systemic delivery of the bioactive agent to, for example, lung tissue without the requirement for biomolecular targeting.

Pharmaceutical formulations containing lipoic acid derivatives and ion pairs thereof are described. The pharmaceutical formulations are useful in the treatment of medical disorders, such as cancer.

The present invention relates to a nanocomplex, and a pharmaceutical composition, a drug delivery system and a drug delivery method using the same. The present nanocomplex consists of a nucleic acid molecule, a monocationic drug and a biocompatible polymer surfactant, and not only has a hydrodynamic size of 10 nm or less, but uniformly distributes as a colloidal form in an aqueous environment. In addition, the nanoscale colloidal formulation of the present invention could protect the nucleic acid molecule from a nuclease (for example, serum nucleases) rich in a physiological environment through the formulation of a stable monocomplex, and provide improvement of cell penetration and in vivo delivery via a micellar structure as well as further protection of the nucleic acid molecule by a micellar passivation. Therefore, the present nanocomplex and a composition and system using the same can deliver an active ingredient (for example, a nucleic acid molecule and monocationic drug) into a cell/tissue of interest in a stable manner, and may be effectively applied for treating or detecting diverse disorders (practically, cancers).

The present invention relates to glucose-responsive hyaluronic acid nanoparticles having boronic acid compounds chemically bonded thereto, and a composition including the same. When the nanoparticles according to the present invention are used, cancer may be diagnosed and treated using a cancer cell-specific biological mechanism, without the use of existing contrast agents and anticancer agents which have the problem of toxicity.

A DDS preparation of a platinum complex, which exhibits a superior antitumor effect required as a medicine and reduced side effects, that is, a clinically usable DDS preparation of a platinum complex, which is conjugated to a polymer carrier that is different from conventional carriers, is desired.

Provided is a polymer conjugate of a platinum(II) complex, the polymer conjugate including: a block copolymer having a polyethylene glycol structural moiety and a polyaspartic acid moiety or a polyglutamic acid moiety; a sulfoxide derivative introduced into a side-chain carboxyl group of the block copolymer; and a platinum(II) complex coordinate-bonded to a sulfoxide group of the sulfoxide derivative.